{"organizations": [], "uuid": "8d0219e5691e9bf8ae4bc35b8864e6cfe5cc3b0c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-spark-therapeutics-enters-into-lic/brief-spark-therapeutics-enters-into-licensing-supply-agreement-for-investigational-voretigene-neparvovec-outside-u-s-idUSASB0C26G", "country": "US", "domain_rank": 408, "title": "BRIEF-Spark Therapeutics Enters Into Licensing, Supply Agreement For Investigational Voretigene Neparvovec Outside U.S.", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-24T23:13:00.000+02:00", "replies_count": 0, "uuid": "8d0219e5691e9bf8ae4bc35b8864e6cfe5cc3b0c"}, "author": "", "url": "https://www.reuters.com/article/brief-spark-therapeutics-enters-into-lic/brief-spark-therapeutics-enters-into-licensing-supply-agreement-for-investigational-voretigene-neparvovec-outside-u-s-idUSASB0C26G", "ord_in_thread": 0, "title": "BRIEF-Spark Therapeutics Enters Into Licensing, Supply Agreement For Investigational Voretigene Neparvovec Outside U.S.", "locations": [], "entities": {"persons": [{"name": "investiga", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "voretigene neparvovec outside u.s. reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "novartis", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 14 PM / in 6 minutes BRIEF-Spark Therapeutics Enters Into Licensing, Supply Agreement For Investigational Voretigene Neparvovec Outside U.S. Reuters Staff 1 Min Read \nJan 24 (Reuters) - Spark Therapeutics Inc: \n* SPARK THERAPEUTICS ENTERS INTO A LICENSING AND SUPPLY AGREEMENT FOR INVESTIGATIONAL VORETIGENE NEPARVOVEC OUTSIDE THE U.S. \n* SPARK THERAPEUTICS INC - SPARK THERAPEUTICS TO RECEIVE $105 MILLION AS AN UPFRONT FEE UNDER AGREEMENT \n* SPARK THERAPEUTICS INC - CO ALSO ENTERED INTO A SEPARATE AGREEMENT TO MANUFACTURE AND SUPPLY INVESTIGATIONAL VORETIGENE NEPARVOVEC TO NOVARTIS \n* SPARK THERAPEUTICS INC - ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $65 MILLION IN CASH MILESTONE PAYMENTS \n* SPARK THERAPEUTICS INC - NO OTHER PROGRAMS IN SPARK THERAPEUTICSâ€™ PIPELINE ARE PART OF THIS AGREEMENT \n* SPARK THERAPEUTICS INC - CO IS ALSO ENTITLED TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF INVESTIGATIONAL VORETIGENE NEPARVOVEC OUTSIDE U.S Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-24T23:13:00.000+02:00", "crawled": "2018-01-24T23:28:03.002+02:00", "highlightTitle": ""}